NCT05279144 (Injection) is a NA clinical trial of Ventroguleal in Application Site Infection, sponsored by Sakarya University.

Who is sponsoring NCT05279144?

NCT05279144 is sponsored by Sakarya University.

What drugs are being tested in NCT05279144?

Interventions in NCT05279144: Ventroguleal.

What condition does NCT05279144 study?

NCT05279144 studies Application Site Infection.

Is NCT05279144 still recruiting?

NCT05279144 is currently completed. Last updated 16 May 2023.

Last reviewed 2023-05-16 · How we verify

NCT05279144: Injection

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Intramuscular Injection From Two Different Sites in Children

Completed NA Last updated 16 May 2023

What this trial tests

NA trial testing Ventroguleal in Application Site Infection in 80 participants. Completed in 30 July 2022.

Timeline

25 March 2022

Primary endpoint
30 May 2022

30 July 2022

Quick facts

Lead sponsor	Sakarya University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	80
Start date	25 March 2022
Primary completion	30 May 2022
Estimated completion	30 July 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Ventroguleal

Conditions studied

Application Site Infection — all drugs for Application Site Infection →

Sponsor

Sakarya University

Who can join

Adults 4 to 6, any sex, with Application Site Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Administration of intramuscular injections (IM) is now common practice in pediatric clinical settings. For this reason, nurses should both update their clinical skills and provide evidence-based practices to children. The aim of this study; The aim of this study is to compare vastus lateralis (VL) and ventrogluteal (VG) region applications in terms of pain and fear in safe and evidence-based intramuscular injection application in children. H0: There is no difference in terms of pain and fear between the children aged 4-6 years who received IM from the vastus lateralis (VL) region and those who received IM from the ventrogluteal (VG) region. H1: Children between the ages of 4 and 6 years IM administered from the vastus lateralis (VL) region have higher pain than those administered IM from the ventrogluteal (VG) region. H2: The fear of children aged 4-6 years who underwent IM from the vastus lateralis (VL) region is higher than that of children who were administered IM from the Ventrogluteal (VG) region.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the effect of intramuscular injection from two different sites on pain and fear in children: a randomized controlled study.
Tiryaki Ö, Menekşe D, Özdemir Ö, Çınar N, et al · · 2024 · cited 1× · PMID 39475919 · DOI 10.1590/1806-9282.20240826

Verify or expand the search:

Other Sakarya University trials

Trials by the same sponsor.

NCT07467655 — THE EFFECT OF DIGITAL STORYTELLING ON NURSING STUDENTS' NURSING PROCESS EDUCATION · NA · not yet recruiting
NCT07508579 — Effect of Hypothermia on BIS and PSI Correlation During Cardiopulmonary Bypass · not yet recruiting
NCT07537335 — Knee Osteoartritis Genicular Nerve RF Ablation vs Alcohol Neurolysis · NA · not yet recruiting
NCT07533669 — Effect of a Preoperative Sensory Modulation Room on Pain, Anxiety, and Sleep in Kidney Transplant Patients · NA · not yet recruiting
NCT07487324 — Oxygenation in Posterior Stabilization Surgery · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05279144 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sakarya University
Last refreshed: 16 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing